\n\tRelated\n<\/p>\n
Fort Worth Report is certified by the Journalism Trust Initiative<\/a> for adhering to standards for ethical journalism.<\/p>\n Republish This Story<\/p>\n
OncoNano Medicine, Inc. announces the appointment of Brent Sorrells as Chief Operating Officer. Bringing more than two decades of experience in product development, strategic operations and commercial execution across the biotechnology industry, Mr. Sorrells will help drive OncoNano\u2019s next phase of growth and operational excellence. <\/p>\n
\u201cBrent joins OncoNano at a pivotal inflection point as we advance our first polymer drug conjugate from our ON-BOARD micelle platform into IND-enabling studies and continue development of ONM-501, our dual-acting STING agonist,\u201d said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano Medicine. \u201cBrent\u2019s extensive operational and leadership experience will be instrumental as we advance our strategic priorities and continue to execute on key growth milestones.\u201d<\/p>\n
Mr. Sorrells most recently served as Vice President of Product Development and Strategy at Allakos, Inc., until its acquisition in May 2025. During his time at Allakos he held various leadership roles in clinical operations. Mr. Sorrells previously held senior roles within the clinical team at ZS Pharma. He has also worked for and served as board chair of a nonprofit business incubator for tech startups. Mr. Sorrells earned a Bachelor of Science in Biology and a Master of Business Administration from the University of North Texas. <\/p>\n
\u201cOncoNano\u2019s vision to redefine how cancer is treated through targeted delivery of medicines to improve their therapeutic index is truly compelling,\u201d said Brent Sorrells. \u201cThe science, the team and the opportunity to make a real difference for patients make this an incredibly exciting time to come on board.\u201d <\/p>\n
About OncoNano Medicine<\/p>\n
OncoNano Medicine, Inc. is a clinical-stage biotechnology company working to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano\u2019s polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment. Our product candidates are designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting. OncoNano is utilizing its polymeric micelle technology to generate a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical needs. Learn more about our platform and pipeline at www.OncoNano.com.<\/p>\n
Read all of our \u201cOn the Move\u201d updates<\/a>.<\/p>\n \n\tRelated\n<\/p>\n Fort Worth Report is certified by the Journalism Trust Initiative<\/a> for adhering to standards for ethical journalism.<\/p>\n Republish This Story<\/p>\n
![\"Creative](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/09\/1758084579_646_cc-by-nd-4.0.png\"\/)
<\/a><\/p>\n